RADAR commentary: Evolution and current status of dosimetry in nuclear medicine

Journal of Nuclear Medicine

Volumn 52, Issue 7, 2011, Pages 1156-1161

  Stabin, Michael G ^a   Sharkey, Robert M ^b   Siegel, Jeffry A ^c  

^a VANDERBILT UNIVERSITY   (United States)

^b CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^c Nuclear Physics Enterprises   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOTATOC Y 90; FLT3 LIGAND; IBRITUMOMAB TIUXETAN; RADIOPHARMACEUTICAL AGENT; SODIUM IODIDE I 131; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; YTTRIUM 90;

BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRACHYTHERAPY; DOSE RESPONSE; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HYPERTHYROIDISM; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; NOTE; NUCLEAR MEDICINE; PRIORITY JOURNAL; RADIATION PROTECTION; RADIOIMMUNOTHERAPY; THYROID CANCER;

HUMANS; NUCLEAR MEDICINE; RADIOMETRY;

EID: 79960324659     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.088666     Document Type: Note

References (41)

1. Marinelli L, Quimby E, Hine G. Dosage determination with radioactive isotopes: practical considerations in therapy and protection. Am J Roentgenol Radium Ther. 1948;59:260-281.
2. Quimby E, Feitelberg S. Radioactive Isotopes in Medicine and Biology. Philadelphia, PA: Lea and Febiger; 1963.
3. Hine G, Brownell G. Radiation Dosimetry. New York, NY: Academic Press; 1956.
4. Loevinger R, Japha E, Brownell G. Discrete radioisotope processes. In: Hine G, Brownell G, eds. Radiation Dosimetry. New York, NY: Academic Press; 1956:694-802.
5. Loevinger R, Berman M. MIRD Pamphlet No. 1, Revised: A Revised Schema for Calculating the Absorbed Dose from Biologically Distributed Radionuclides. New York, NY: Society of Nuclear Medicine; 1976.
6. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys. 2003;85:294-310. (Pubitemid 36999340)
7. 131I- tositumomab therapy. J Nucl Med. 2002;43:354-363.
8. Kobe C, Eschner W, Sudbrock F, et al. Graves' disease and radioiodine therapy: is success of ablation dependent on the achieved dose above 200 Gy? Nuklearmedizin. 2008;47:13-17.
9. Flux GD, Haq M, Chittenden SJ, et al. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37:270-275.
10. Jonsson H, Mattsson S. Excess radiation absorbed doses from non-optimized radioiodine treatment of hyperthyroidism. Radiat Prot Dosimetry. 2004;108:107-114. (Pubitemid 38324494)
11. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329:1219-1224. (Pubitemid 23306322)
12. Press OW, Eary JF, Badger CC, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol. 1989;7:1027-1038. (Pubitemid 19196525)
13. Juweid ME, Sharkey RM, Behr T, et al. Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab′)2. J Nucl Med. 1996;37:1504-1510. (Pubitemid 26321631)
14. Wahl RL, Zasadny KR, MacFarlane D, et al. Iodine-131 anti-B1 antibody for Bcell lymphoma: an update on the Michigan phase I experience. J Nucl Med. 1998;39(suppl)21S-27S.
15. 131I-tositumomab. J Nucl Med. 2010;51:1878-1884.
16. Siegel JA. Establishing a clinically meaningful predictive model of hematologic toxicity in nonmyeloablative targeted radiotherapy: practical aspects and limitations of red marrow dosimetry. Cancer Biother Radiopharm. 2005;20:126-140. (Pubitemid 40696094)
17. Shen S, Meredith RF, Duan J, et al. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting 90Y-antibody therapy. J Nucl Med. 2002;43:1245-1253. (Pubitemid 34988774)
18. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689-694. (Pubitemid 23115673)
19. Mirallie E, Vuillez JP, Bardet S, et al. High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab. 2005;90:779-788. (Pubitemid 40279196)
20. Chatal JF, Campion L, Kraeber-Bodere F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonicantigen radioimmunotherapy: a collaborative study with the French endocrine tumor group. J Clin Oncol. 2006;24:1705-1711. (Pubitemid 46622142)
21. Kraeber-Bodere F, Goldenberg DM, Chatal JF, Barbet J. Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer. Curr Oncol. 2009;16:3-8.
22. Siegel JA, Yeldell D, Goldenberg DM, et al. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med. 2003;44:67-76. (Pubitemid 36077714)
23. Shen S, Duan J, Meredith RF. Model prediction of treatment planning for dose-fractionated radioimmunotherapy. Cancer. 2002;94:1264-1269. (Pubitemid 34150888)
24. 90Y-labeled somatostatin analogs. J Nucl Med. 2005;46(suppl):92S-98S.
25. 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med. 2003;44:260-268.
26. 90Y-epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med. 2003;44:2000-2018.
27. Koral KF, Kaminski MS, Wahl RL. Correlation of tumor radiation-absorbed dose with response is easier to find in previously untreated patients. J Nucl Med. 2003;44:1541-1543.
28. DeNardo SJ, Williams LF, Leigh BR, Wahl RL. Choosing an optimal radioimmunotherapy dose for clinical response. Cancer. 2002;94:1275-1286. (Pubitemid 34150890)
29. 2 is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother. 2002;51:15-24.
30. Hernandez MC, Knox SJ. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2004;59:1274-1287. (Pubitemid 38954048)
31. Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, Mihatsch MJ. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis. 2001;37:847-851. (Pubitemid 32268047)
32. 90Y-DOTATOC. Eur J Nucl Med. 2001;28:1552-1554.
33. Behr TM, Béhé M, Kluge G, et al. Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis. Eur J Nucl Med Mol Imaging. 2002;29:277-279. (Pubitemid 34143464)
34. 166Ho-DOTMP. Cancer Biother Radiopharm. 2003;18:225-230.
35. Breitz HB, Wendt RE III, Stabin MS, et al. 166Ho-DOTMP radiationabsorbed dose estimation for skeletal targeted radiotherapy. J Nucl Med. 2006;47:534-542. (Pubitemid 46768497)
36. 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46(suppl):99S-106S.
37. 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847-1856.
38. Wessels BW, Konijnenberg MW, Dale RG, et al. MIRD Pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response-implications for radionuclide therapy. J Nucl Med. 2008;49:1884-1899.
39. Siegel JA, Stabin MG, Sharkey RM. Renal dosimetry in peptide radionuclide receptor therapy. Cancer Biother Radiopharm. 2010;25:581-588.
40. Kaminski MS, Estes J, Tuck M, et al. Iodine I 131 tositumomab therapy for previously untreated follicular lymphoma (FL) [abstract]. Proc Am Soc Clin Oncol. 2000;19(suppl):5A.
41. Stabin MG. The case for patient-specific dosimetry in radionuclide therapy. Cancer Biother Radiopharm. 2008;23:273-284. (Pubitemid 351931455)